CAR T CELL THERAPY MARKET ANALYSIS
Global CAR T Cell Therapy Market: Key Developments
In June 2022, Bristol-Myers Squibb Company, one of the global leader in Biopharmaceutical company, obtained the U.S. Food and Drug Administration (FDA), approval for Breyanzi CAR T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma after one prior therapy. Approval was based on data from the Phase 2 pilot company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL.
In February, 2022, Johnson & Johnson Services, Inc., one of the largest healthcare company, announced that, the U.S. Food and Drug Administration approved CARVYKTI (ciltacabtagene autoleucel), a BCMA-Directed CAR-T Immunotherapy for the treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
